Biogen Pharmachem Industries L (BIOGEN.BO) Stock Competitors & Peer Comparison
See (BIOGEN.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Investment - Banking & Investment Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIOGEN.BO | ₹0.33 | -5.71% | 306.9M | 34.00 | ₹0.01 | N/A |
| MEDIASSIST.NS | ₹353.90 | -1.41% | 26.7B | 29.38 | ₹12.16 | N/A |
| AQFINTECH.BO | ₹1,226.85 | -0.16% | 19.2B | 1095.40 | ₹1.12 | N/A |
| LKPFIN.BO | ₹175.05 | -3.07% | 11.2B | -550.00 | -₹0.32 | N/A |
| AKCAPIT.BO | ₹1,720.00 | -0.25% | 11.2B | 10.14 | ₹167.20 | +3.07% |
| INDPRUD.BO | ₹6,434.10 | +3.51% | 10.6B | 16.64 | ₹380.19 | +1.74% |
| MASTERTR.BO | ₹93.30 | +14.41% | 10.1B | 7.72 | ₹10.60 | N/A |
| GCSL.BO | ₹421.50 | +2.69% | 9.5B | 35.12 | ₹11.90 | +0.11% |
| SYSTMTXC.BO | ₹67.15 | +2.25% | 9B | 31.36 | ₹2.10 | +0.15% |
| ARYAMAN.BO | ₹590.00 | +0.83% | 7.2B | 18.99 | ₹31.13 | N/A |
Stock Comparison
BIOGEN.BO vs MEDIASSIST.NS Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, MEDIASSIST.NS has a market cap of 26.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while MEDIASSIST.NS trades at ₹353.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas MEDIASSIST.NS's P/E ratio is 29.38. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MEDIASSIST.NS's ROE of +0.14%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MEDIASSIST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MEDIASSIST.NS's competition here
BIOGEN.BO vs AQFINTECH.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, AQFINTECH.BO has a market cap of 19.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while AQFINTECH.BO trades at ₹1,226.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas AQFINTECH.BO's P/E ratio is 1095.40. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to AQFINTECH.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is more volatile compared to AQFINTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check AQFINTECH.BO's competition here
BIOGEN.BO vs LKPFIN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, LKPFIN.BO has a market cap of 11.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while LKPFIN.BO trades at ₹175.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas LKPFIN.BO's P/E ratio is -550.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to LKPFIN.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to LKPFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check LKPFIN.BO's competition here
BIOGEN.BO vs AKCAPIT.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, AKCAPIT.BO has a market cap of 11.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while AKCAPIT.BO trades at ₹1,720.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas AKCAPIT.BO's P/E ratio is 10.14. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to AKCAPIT.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to AKCAPIT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check AKCAPIT.BO's competition here
BIOGEN.BO vs INDPRUD.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, INDPRUD.BO has a market cap of 10.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while INDPRUD.BO trades at ₹6,434.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas INDPRUD.BO's P/E ratio is 16.64. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to INDPRUD.BO's ROE of +0.08%. Regarding short-term risk, BIOGEN.BO is more volatile compared to INDPRUD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check INDPRUD.BO's competition here
BIOGEN.BO vs MASTERTR.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, MASTERTR.BO has a market cap of 10.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while MASTERTR.BO trades at ₹93.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas MASTERTR.BO's P/E ratio is 7.72. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MASTERTR.BO's ROE of +0.18%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MASTERTR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MASTERTR.BO's competition here
BIOGEN.BO vs GCSL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, GCSL.BO has a market cap of 9.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while GCSL.BO trades at ₹421.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas GCSL.BO's P/E ratio is 35.12. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GCSL.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GCSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GCSL.BO's competition here
BIOGEN.BO vs SYSTMTXC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SYSTMTXC.BO has a market cap of 9B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SYSTMTXC.BO trades at ₹67.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SYSTMTXC.BO's P/E ratio is 31.36. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SYSTMTXC.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SYSTMTXC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SYSTMTXC.BO's competition here
BIOGEN.BO vs ARYAMAN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ARYAMAN.BO has a market cap of 7.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ARYAMAN.BO trades at ₹590.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ARYAMAN.BO's P/E ratio is 18.99. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARYAMAN.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ARYAMAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARYAMAN.BO's competition here
BIOGEN.BO vs SRAMSET.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SRAMSET.BO has a market cap of 5.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SRAMSET.BO trades at ₹290.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SRAMSET.BO's P/E ratio is -24.45. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SRAMSET.BO's ROE of -0.18%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SRAMSET.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SRAMSET.BO's competition here
BIOGEN.BO vs ARYACAPM.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ARYACAPM.BO has a market cap of 4.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ARYACAPM.BO trades at ₹401.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ARYACAPM.BO's P/E ratio is 17.31. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARYACAPM.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARYACAPM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARYACAPM.BO's competition here
BIOGEN.BO vs KIRANVYPAR.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, KIRANVYPAR.BO has a market cap of 4.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while KIRANVYPAR.BO trades at ₹167.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas KIRANVYPAR.BO's P/E ratio is 862.75. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to KIRANVYPAR.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is more volatile compared to KIRANVYPAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check KIRANVYPAR.BO's competition here
BIOGEN.BO vs OIVL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, OIVL.BO has a market cap of 3.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while OIVL.BO trades at ₹6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas OIVL.BO's P/E ratio is -1.03. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to OIVL.BO's ROE of +0.44%. Regarding short-term risk, BIOGEN.BO is less volatile compared to OIVL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check OIVL.BO's competition here
BIOGEN.BO vs NIDHGRN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, NIDHGRN.BO has a market cap of 3.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while NIDHGRN.BO trades at ₹425.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas NIDHGRN.BO's P/E ratio is 68.98. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to NIDHGRN.BO's ROE of +0.43%. Regarding short-term risk, BIOGEN.BO is more volatile compared to NIDHGRN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check NIDHGRN.BO's competition here
BIOGEN.BO vs ALSL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ALSL.BO has a market cap of 3.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ALSL.BO trades at ₹69.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ALSL.BO's P/E ratio is 51.67. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ALSL.BO's ROE of +0.08%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ALSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ALSL.BO's competition here
BIOGEN.BO vs IMCAP.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, IMCAP.BO has a market cap of 3.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while IMCAP.BO trades at ₹914.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas IMCAP.BO's P/E ratio is 229.89. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to IMCAP.BO's ROE of +0.29%. Regarding short-term risk, BIOGEN.BO is more volatile compared to IMCAP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check IMCAP.BO's competition here
BIOGEN.BO vs HAMPTON.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, HAMPTON.BO has a market cap of 2.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while HAMPTON.BO trades at ₹9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas HAMPTON.BO's P/E ratio is -15.65. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to HAMPTON.BO's ROE of -0.09%. Regarding short-term risk, BIOGEN.BO is more volatile compared to HAMPTON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check HAMPTON.BO's competition here
BIOGEN.BO vs UCIL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, UCIL.BO has a market cap of 2.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while UCIL.BO trades at ₹67.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas UCIL.BO's P/E ratio is 2.79. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to UCIL.BO's ROE of +0.73%. Regarding short-term risk, BIOGEN.BO is more volatile compared to UCIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check UCIL.BO's competition here
BIOGEN.BO vs PHCAP.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, PHCAP.BO has a market cap of 2.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while PHCAP.BO trades at ₹872.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas PHCAP.BO's P/E ratio is 81.43. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PHCAP.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PHCAP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PHCAP.BO's competition here
BIOGEN.BO vs QUESTCAP.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, QUESTCAP.BO has a market cap of 2.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while QUESTCAP.BO trades at ₹261.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas QUESTCAP.BO's P/E ratio is 6.54. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to QUESTCAP.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to QUESTCAP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check QUESTCAP.BO's competition here
BIOGEN.BO vs SHARDUL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SHARDUL.BO has a market cap of 2.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SHARDUL.BO trades at ₹27.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SHARDUL.BO's P/E ratio is -4.73. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SHARDUL.BO's ROE of -0.07%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SHARDUL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SHARDUL.BO's competition here
BIOGEN.BO vs REGENCY.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, REGENCY.BO has a market cap of 2.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while REGENCY.BO trades at ₹33.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas REGENCY.BO's P/E ratio is 22.24. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to REGENCY.BO's ROE of +0.10%. Regarding short-term risk, BIOGEN.BO is less volatile compared to REGENCY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check REGENCY.BO's competition here
BIOGEN.BO vs VISCO.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, VISCO.BO has a market cap of 2.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while VISCO.BO trades at ₹92.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas VISCO.BO's P/E ratio is 7.50. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to VISCO.BO's ROE of -0.08%. Regarding short-term risk, BIOGEN.BO is more volatile compared to VISCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check VISCO.BO's competition here
BIOGEN.BO vs SODFC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SODFC.BO has a market cap of 2.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SODFC.BO trades at ₹124.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SODFC.BO's P/E ratio is -1782.86. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SODFC.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SODFC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SODFC.BO's competition here
BIOGEN.BO vs TAMBOLIIN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, TAMBOLIIN.BO has a market cap of 1.9B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while TAMBOLIIN.BO trades at ₹181.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas TAMBOLIIN.BO's P/E ratio is 19.02. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to TAMBOLIIN.BO's ROE of +0.08%. Regarding short-term risk, BIOGEN.BO is more volatile compared to TAMBOLIIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check TAMBOLIIN.BO's competition here
BIOGEN.BO vs PROFINC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, PROFINC.BO has a market cap of 1.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while PROFINC.BO trades at ₹2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas PROFINC.BO's P/E ratio is -312.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PROFINC.BO's ROE of -0.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PROFINC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PROFINC.BO's competition here
BIOGEN.BO vs JHACC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, JHACC.BO has a market cap of 1.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while JHACC.BO trades at ₹167.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas JHACC.BO's P/E ratio is 129.62. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to JHACC.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is less volatile compared to JHACC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check JHACC.BO's competition here
BIOGEN.BO vs PMCFIN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, PMCFIN.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while PMCFIN.BO trades at ₹1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas PMCFIN.BO's P/E ratio is 22.56. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PMCFIN.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PMCFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PMCFIN.BO's competition here
BIOGEN.BO vs LKPSEC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, LKPSEC.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while LKPSEC.BO trades at ₹17.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas LKPSEC.BO's P/E ratio is 13.92. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to LKPSEC.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to LKPSEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check LKPSEC.BO's competition here
BIOGEN.BO vs ARIHCAPM.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ARIHCAPM.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ARIHCAPM.BO trades at ₹68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ARIHCAPM.BO's P/E ratio is 8.17. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARIHCAPM.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ARIHCAPM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARIHCAPM.BO's competition here
BIOGEN.BO vs CGFL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, CGFL.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while CGFL.BO trades at ₹25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas CGFL.BO's P/E ratio is 5.19. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to CGFL.BO's ROE of +0.37%. Regarding short-term risk, BIOGEN.BO is less volatile compared to CGFL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check CGFL.BO's competition here
BIOGEN.BO vs DHARNI.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, DHARNI.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while DHARNI.BO trades at ₹65.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas DHARNI.BO's P/E ratio is 46.50. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to DHARNI.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is more volatile compared to DHARNI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check DHARNI.BO's competition here
BIOGEN.BO vs UPSURGE.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, UPSURGE.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while UPSURGE.BO trades at ₹57.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas UPSURGE.BO's P/E ratio is 40.40. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to UPSURGE.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to UPSURGE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check UPSURGE.BO's competition here
BIOGEN.BO vs PIONRINV.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, PIONRINV.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while PIONRINV.BO trades at ₹107.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas PIONRINV.BO's P/E ratio is 7.60. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PIONRINV.BO's ROE of +0.10%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PIONRINV.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PIONRINV.BO's competition here
BIOGEN.BO vs SWASTIKA.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SWASTIKA.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SWASTIKA.BO trades at ₹62.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SWASTIKA.BO's P/E ratio is 9.57. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SWASTIKA.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SWASTIKA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SWASTIKA.BO's competition here
BIOGEN.BO vs SCL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SCL.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SCL.BO trades at ₹0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SCL.BO's P/E ratio is 4.60. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SCL.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SCL.BO's competition here
BIOGEN.BO vs INDUSFINL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, INDUSFINL.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while INDUSFINL.BO trades at ₹123.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas INDUSFINL.BO's P/E ratio is 58.40. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to INDUSFINL.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is more volatile compared to INDUSFINL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check INDUSFINL.BO's competition here
BIOGEN.BO vs ESCORP.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ESCORP.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ESCORP.BO trades at ₹100.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ESCORP.BO's P/E ratio is 37.31. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ESCORP.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ESCORP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ESCORP.BO's competition here
BIOGEN.BO vs VGCL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, VGCL.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while VGCL.BO trades at ₹49.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas VGCL.BO's P/E ratio is 6.25. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to VGCL.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to VGCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check VGCL.BO's competition here
BIOGEN.BO vs TITANSEC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, TITANSEC.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while TITANSEC.BO trades at ₹43.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas TITANSEC.BO's P/E ratio is 9.89. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to TITANSEC.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to TITANSEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check TITANSEC.BO's competition here
BIOGEN.BO vs NAYSAA.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, NAYSAA.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while NAYSAA.BO trades at ₹307.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas NAYSAA.BO's P/E ratio is 379.26. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to NAYSAA.BO's ROE of +0.57%. Regarding short-term risk, BIOGEN.BO is less volatile compared to NAYSAA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check NAYSAA.BO's competition here
BIOGEN.BO vs AARNAV.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, AARNAV.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while AARNAV.BO trades at ₹24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas AARNAV.BO's P/E ratio is 14.82. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to AARNAV.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is more volatile compared to AARNAV.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check AARNAV.BO's competition here
BIOGEN.BO vs MUNCAPM.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, MUNCAPM.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while MUNCAPM.BO trades at ₹115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas MUNCAPM.BO's P/E ratio is 522.73. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MUNCAPM.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MUNCAPM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MUNCAPM.BO's competition here
BIOGEN.BO vs SAUMYA.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SAUMYA.BO has a market cap of 1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SAUMYA.BO trades at ₹146.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SAUMYA.BO's P/E ratio is -29.50. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SAUMYA.BO's ROE of -0.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SAUMYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SAUMYA.BO's competition here
BIOGEN.BO vs ASITCFIN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ASITCFIN.BO has a market cap of 997.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ASITCFIN.BO trades at ₹121.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ASITCFIN.BO's P/E ratio is -62.37. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ASITCFIN.BO's ROE of -0.07%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ASITCFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ASITCFIN.BO's competition here
BIOGEN.BO vs VISTARAMAR.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, VISTARAMAR.BO has a market cap of 933.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while VISTARAMAR.BO trades at ₹166.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas VISTARAMAR.BO's P/E ratio is 9.98. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to VISTARAMAR.BO's ROE of +0.20%. Regarding short-term risk, BIOGEN.BO is less volatile compared to VISTARAMAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check VISTARAMAR.BO's competition here
BIOGEN.BO vs ASSAMENT.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ASSAMENT.BO has a market cap of 908.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ASSAMENT.BO trades at ₹631.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ASSAMENT.BO's P/E ratio is 19.54. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ASSAMENT.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ASSAMENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ASSAMENT.BO's competition here
BIOGEN.BO vs MUKESHB.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, MUKESHB.BO has a market cap of 840M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while MUKESHB.BO trades at ₹126.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas MUKESHB.BO's P/E ratio is 13.26. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MUKESHB.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MUKESHB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MUKESHB.BO's competition here
BIOGEN.BO vs ADVIKCA.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ADVIKCA.BO has a market cap of 803.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ADVIKCA.BO trades at ₹1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ADVIKCA.BO's P/E ratio is -3.57. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ADVIKCA.BO's ROE of -0.10%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ADVIKCA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ADVIKCA.BO's competition here
BIOGEN.BO vs CHRTEDCA.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, CHRTEDCA.BO has a market cap of 797.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while CHRTEDCA.BO trades at ₹264.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas CHRTEDCA.BO's P/E ratio is 29.41. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to CHRTEDCA.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to CHRTEDCA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check CHRTEDCA.BO's competition here
BIOGEN.BO vs ROYALIND.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ROYALIND.BO has a market cap of 750.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ROYALIND.BO trades at ₹6.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ROYALIND.BO's P/E ratio is 14.13. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ROYALIND.BO's ROE of +0.20%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ROYALIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ROYALIND.BO's competition here
BIOGEN.BO vs WALLFORT.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, WALLFORT.BO has a market cap of 725.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while WALLFORT.BO trades at ₹74.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas WALLFORT.BO's P/E ratio is -24.16. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to WALLFORT.BO's ROE of -0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to WALLFORT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check WALLFORT.BO's competition here
BIOGEN.BO vs GOGIACAP.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, GOGIACAP.BO has a market cap of 719M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while GOGIACAP.BO trades at ₹113.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas GOGIACAP.BO's P/E ratio is -2.98. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GOGIACAP.BO's ROE of -0.01%. Regarding short-term risk, BIOGEN.BO is more volatile compared to GOGIACAP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOGIACAP.BO's competition here
BIOGEN.BO vs MYMONEY.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, MYMONEY.BO has a market cap of 689.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while MYMONEY.BO trades at ₹41.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas MYMONEY.BO's P/E ratio is -75.96. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MYMONEY.BO's ROE of -0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MYMONEY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MYMONEY.BO's competition here
BIOGEN.BO vs SKPSEC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SKPSEC.BO has a market cap of 682.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SKPSEC.BO trades at ₹105.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SKPSEC.BO's P/E ratio is 6.59. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SKPSEC.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SKPSEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SKPSEC.BO's competition here
BIOGEN.BO vs JOINDRE.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, JOINDRE.BO has a market cap of 678.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while JOINDRE.BO trades at ₹49.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas JOINDRE.BO's P/E ratio is 8.70. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to JOINDRE.BO's ROE of +0.17%. Regarding short-term risk, BIOGEN.BO is more volatile compared to JOINDRE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check JOINDRE.BO's competition here
BIOGEN.BO vs BNRSEC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, BNRSEC.BO has a market cap of 673.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while BNRSEC.BO trades at ₹16.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas BNRSEC.BO's P/E ratio is 7.17. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to BNRSEC.BO's ROE of +0.13%. Regarding short-term risk, BIOGEN.BO is more volatile compared to BNRSEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check BNRSEC.BO's competition here
BIOGEN.BO vs HBPOR.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, HBPOR.BO has a market cap of 647M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while HBPOR.BO trades at ₹62.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas HBPOR.BO's P/E ratio is 39.29. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to HBPOR.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is more volatile compared to HBPOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check HBPOR.BO's competition here
BIOGEN.BO vs GOWRALE.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, GOWRALE.BO has a market cap of 643.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while GOWRALE.BO trades at ₹82.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas GOWRALE.BO's P/E ratio is 8.76. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GOWRALE.BO's ROE of +0.16%. Regarding short-term risk, BIOGEN.BO is more volatile compared to GOWRALE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOWRALE.BO's competition here
BIOGEN.BO vs BAMPSL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, BAMPSL.BO has a market cap of 627.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while BAMPSL.BO trades at ₹18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas BAMPSL.BO's P/E ratio is 31.79. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to BAMPSL.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to BAMPSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check BAMPSL.BO's competition here
BIOGEN.BO vs ELIXIR.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ELIXIR.BO has a market cap of 607.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ELIXIR.BO trades at ₹108.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ELIXIR.BO's P/E ratio is 27.69. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ELIXIR.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ELIXIR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ELIXIR.BO's competition here
BIOGEN.BO vs DHANCOT.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, DHANCOT.BO has a market cap of 588.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while DHANCOT.BO trades at ₹120.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas DHANCOT.BO's P/E ratio is 755.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to DHANCOT.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is more volatile compared to DHANCOT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check DHANCOT.BO's competition here
BIOGEN.BO vs LADDERUP.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, LADDERUP.BO has a market cap of 549.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while LADDERUP.BO trades at ₹51.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas LADDERUP.BO's P/E ratio is 34.11. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to LADDERUP.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is more volatile compared to LADDERUP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check LADDERUP.BO's competition here
BIOGEN.BO vs MEFCOMCAP.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, MEFCOMCAP.BO has a market cap of 520.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while MEFCOMCAP.BO trades at ₹11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas MEFCOMCAP.BO's P/E ratio is -40.68. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MEFCOMCAP.BO's ROE of -0.10%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MEFCOMCAP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MEFCOMCAP.BO's competition here
BIOGEN.BO vs ISLCONSUL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ISLCONSUL.BO has a market cap of 500.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ISLCONSUL.BO trades at ₹22.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ISLCONSUL.BO's P/E ratio is -59.54. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ISLCONSUL.BO's ROE of -0.16%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ISLCONSUL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ISLCONSUL.BO's competition here
BIOGEN.BO vs MEAPL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, MEAPL.BO has a market cap of 489.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while MEAPL.BO trades at ₹31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas MEAPL.BO's P/E ratio is 2.87. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MEAPL.BO's ROE of +0.31%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MEAPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MEAPL.BO's competition here
BIOGEN.BO vs SMIFS.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SMIFS.BO has a market cap of 479.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SMIFS.BO trades at ₹81.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SMIFS.BO's P/E ratio is 41.44. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SMIFS.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SMIFS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SMIFS.BO's competition here
BIOGEN.BO vs BRIDGESE.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, BRIDGESE.BO has a market cap of 463.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while BRIDGESE.BO trades at ₹14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas BRIDGESE.BO's P/E ratio is 35.88. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to BRIDGESE.BO's ROE of +0.37%. Regarding short-term risk, BIOGEN.BO is less volatile compared to BRIDGESE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check BRIDGESE.BO's competition here
BIOGEN.BO vs SITAENT.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SITAENT.BO has a market cap of 459.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SITAENT.BO trades at ₹154.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SITAENT.BO's P/E ratio is 8.75. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SITAENT.BO's ROE of +0.27%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SITAENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SITAENT.BO's competition here
BIOGEN.BO vs SAICAPI.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SAICAPI.BO has a market cap of 430.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SAICAPI.BO trades at ₹147.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SAICAPI.BO's P/E ratio is 3.43. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SAICAPI.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SAICAPI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SAICAPI.BO's competition here
BIOGEN.BO vs SRESTHA.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SRESTHA.BO has a market cap of 421.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SRESTHA.BO trades at ₹0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SRESTHA.BO's P/E ratio is -1.04. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SRESTHA.BO's ROE of -0.28%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SRESTHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SRESTHA.BO's competition here
BIOGEN.BO vs PANINDIAC.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, PANINDIAC.BO has a market cap of 409.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while PANINDIAC.BO trades at ₹1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas PANINDIAC.BO's P/E ratio is -191.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PANINDIAC.BO's ROE of -0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PANINDIAC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PANINDIAC.BO's competition here
BIOGEN.BO vs NAM.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, NAM.BO has a market cap of 406.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while NAM.BO trades at ₹75.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas NAM.BO's P/E ratio is 198.39. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to NAM.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to NAM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check NAM.BO's competition here
BIOGEN.BO vs ANUPAM.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ANUPAM.BO has a market cap of 383.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ANUPAM.BO trades at ₹2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ANUPAM.BO's P/E ratio is 22.44. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ANUPAM.BO's ROE of +0.07%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ANUPAM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ANUPAM.BO's competition here
BIOGEN.BO vs AJCON.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, AJCON.BO has a market cap of 370.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while AJCON.BO trades at ₹6.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas AJCON.BO's P/E ratio is -606.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to AJCON.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to AJCON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check AJCON.BO's competition here
BIOGEN.BO vs KIDUJA.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, KIDUJA.BO has a market cap of 345.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while KIDUJA.BO trades at ₹14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas KIDUJA.BO's P/E ratio is 15.48. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to KIDUJA.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to KIDUJA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check KIDUJA.BO's competition here
BIOGEN.BO vs SPCAPIT.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SPCAPIT.BO has a market cap of 342.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SPCAPIT.BO trades at ₹55.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SPCAPIT.BO's P/E ratio is 9.73. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SPCAPIT.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SPCAPIT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SPCAPIT.BO's competition here
BIOGEN.BO vs SHRINIWAS.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SHRINIWAS.BO has a market cap of 337.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SHRINIWAS.BO trades at ₹10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SHRINIWAS.BO's P/E ratio is 0.04. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SHRINIWAS.BO's ROE of -1.70%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SHRINIWAS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SHRINIWAS.BO's competition here
BIOGEN.BO vs ARNOLD.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ARNOLD.BO has a market cap of 319.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ARNOLD.BO trades at ₹13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ARNOLD.BO's P/E ratio is 29.20. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARNOLD.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ARNOLD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARNOLD.BO's competition here
BIOGEN.BO vs GOLDLINE.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, GOLDLINE.BO has a market cap of 317.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while GOLDLINE.BO trades at ₹0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas GOLDLINE.BO's P/E ratio is 610.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GOLDLINE.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GOLDLINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOLDLINE.BO's competition here
BIOGEN.BO vs SUMEDHA.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SUMEDHA.BO has a market cap of 314.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SUMEDHA.BO trades at ₹39.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SUMEDHA.BO's P/E ratio is 13.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SUMEDHA.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SUMEDHA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SUMEDHA.BO's competition here
BIOGEN.BO vs GALACTICO.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, GALACTICO.BO has a market cap of 306.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while GALACTICO.BO trades at ₹1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas GALACTICO.BO's P/E ratio is 28.71. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GALACTICO.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to GALACTICO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check GALACTICO.BO's competition here
BIOGEN.BO vs ARUNIS.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ARUNIS.BO has a market cap of 300.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ARUNIS.BO trades at ₹96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ARUNIS.BO's P/E ratio is 58.65. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARUNIS.BO's ROE of +0.37%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ARUNIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARUNIS.BO's competition here
BIOGEN.BO vs PURSHOTTAM.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, PURSHOTTAM.BO has a market cap of 282.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while PURSHOTTAM.BO trades at ₹34.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas PURSHOTTAM.BO's P/E ratio is 35.93. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PURSHOTTAM.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PURSHOTTAM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PURSHOTTAM.BO's competition here
BIOGEN.BO vs ABHIFIN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, ABHIFIN.BO has a market cap of 279.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while ABHIFIN.BO trades at ₹60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas ABHIFIN.BO's P/E ratio is 1008.33. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ABHIFIN.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ABHIFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ABHIFIN.BO's competition here
BIOGEN.BO vs INDIANVSH.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, INDIANVSH.BO has a market cap of 279M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while INDIANVSH.BO trades at ₹7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas INDIANVSH.BO's P/E ratio is -3.17. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to INDIANVSH.BO's ROE of +0.22%. Regarding short-term risk, BIOGEN.BO is less volatile compared to INDIANVSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check INDIANVSH.BO's competition here
BIOGEN.BO vs SULABEN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, SULABEN.BO has a market cap of 273.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while SULABEN.BO trades at ₹2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas SULABEN.BO's P/E ratio is 12.36. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SULABEN.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SULABEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SULABEN.BO's competition here
BIOGEN.BO vs BERVINL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, BERVINL.BO has a market cap of 271.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while BERVINL.BO trades at ₹45.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas BERVINL.BO's P/E ratio is -1.65. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to BERVINL.BO's ROE of -0.69%. Regarding short-term risk, BIOGEN.BO is less volatile compared to BERVINL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check BERVINL.BO's competition here
BIOGEN.BO vs RAMSONS.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, RAMSONS.BO has a market cap of 269.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while RAMSONS.BO trades at ₹87.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas RAMSONS.BO's P/E ratio is 3.57. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to RAMSONS.BO's ROE of +0.41%. Regarding short-term risk, BIOGEN.BO is more volatile compared to RAMSONS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check RAMSONS.BO's competition here
BIOGEN.BO vs STANROS.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, STANROS.BO has a market cap of 265.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while STANROS.BO trades at ₹67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas STANROS.BO's P/E ratio is -8.82. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to STANROS.BO's ROE of -0.08%. Regarding short-term risk, BIOGEN.BO is more volatile compared to STANROS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check STANROS.BO's competition here
BIOGEN.BO vs KJMCFIN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, KJMCFIN.BO has a market cap of 257.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while KJMCFIN.BO trades at ₹52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas KJMCFIN.BO's P/E ratio is 17.12. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to KJMCFIN.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to KJMCFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check KJMCFIN.BO's competition here
BIOGEN.BO vs GSBFIN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, GSBFIN.BO has a market cap of 239.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while GSBFIN.BO trades at ₹38.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas GSBFIN.BO's P/E ratio is -221.94. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GSBFIN.BO's ROE of -0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GSBFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GSBFIN.BO's competition here
BIOGEN.BO vs CUBIFIN.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, CUBIFIN.BO has a market cap of 235.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while CUBIFIN.BO trades at ₹3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas CUBIFIN.BO's P/E ratio is 120.67. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to CUBIFIN.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is more volatile compared to CUBIFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check CUBIFIN.BO's competition here
BIOGEN.BO vs HELPAGE.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, HELPAGE.BO has a market cap of 222.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while HELPAGE.BO trades at ₹22.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas HELPAGE.BO's P/E ratio is 7.56. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to HELPAGE.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is more volatile compared to HELPAGE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check HELPAGE.BO's competition here
BIOGEN.BO vs KJMCCORP.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, KJMCCORP.BO has a market cap of 215.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while KJMCCORP.BO trades at ₹54.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas KJMCCORP.BO's P/E ratio is 11.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to KJMCCORP.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to KJMCCORP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check KJMCCORP.BO's competition here
BIOGEN.BO vs VERTEX.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, VERTEX.BO has a market cap of 209M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while VERTEX.BO trades at ₹2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas VERTEX.BO's P/E ratio is -8.84. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to VERTEX.BO's ROE of -0.25%. Regarding short-term risk, BIOGEN.BO is less volatile compared to VERTEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check VERTEX.BO's competition here
BIOGEN.BO vs STEP2COR.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, STEP2COR.BO has a market cap of 208.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while STEP2COR.BO trades at ₹28.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas STEP2COR.BO's P/E ratio is -11.47. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to STEP2COR.BO's ROE of +0.25%. Regarding short-term risk, BIOGEN.BO is more volatile compared to STEP2COR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check STEP2COR.BO's competition here
BIOGEN.BO vs PHOTON.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, PHOTON.BO has a market cap of 201.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while PHOTON.BO trades at ₹139.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas PHOTON.BO's P/E ratio is 457.24. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PHOTON.BO's ROE of -0.07%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PHOTON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PHOTON.BO's competition here
BIOGEN.BO vs RFSL.BO Comparison June 2026
BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 306.9M. In comparison, RFSL.BO has a market cap of 193.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.33, while RFSL.BO trades at ₹26.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 34.00, whereas RFSL.BO's P/E ratio is 71.84. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to RFSL.BO's ROE of +0.07%. Regarding short-term risk, BIOGEN.BO is more volatile compared to RFSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check RFSL.BO's competition here